April 23, 2024

CDMO Live Europe 2026

CDMO Live Europe 2026

19-21 May 2026, Rotterdam

Join Europe’s Premier External Manufacturing Community at CDMO Live 2026

We are pleased to offer BioRN members 20% discount for CDMO Live Europe

CDMO Live Europe 2026 is the global meeting place for leaders in outsourced biopharma development and manufacturing.

Across three days in Rotterdam, you’ll gain actionable insights, connect with partners through curated one-to-one meetings, and experience networking like no other.

550+ external manufacturing leaders and 90+ CDMOs are gathering at CDMO Live Europe (19-21 May, Rotterdam) – the most valuable and efficient event for external manufacturing in 2026.

Our commitment is that no other external manufacturing event will give you more strategic value in 2026.

Tickets include:

Training Sessions – Biotech CMC Bootcamp and Strategic Partnership training sessions designed for practical application, not theory
PartnerMatch meetings – Pre-scheduled 1-2-1s with 90+ CDMOs matching your specific requirements. No wasted conversations.
20 Outsourcing Excellence Roundtables – Peer-led discussions on supplier management, capacity planning, AI in manufacturing and Decarbonization with the PSCI
40+ Manufacturing Experts Across 3 Tracks featuring analysts and executives from MSD, Roche, AstraZeneca, Daiichi Sankyo, Sandoz, J&J, Bayer and leading biotech companies
Unique Networking Experiences – including Cycle Tour, Rotterdam Run, and the exclusive Boat Party to create connections

Find out more: https://pharmasource.global/events/cdmolive/

BioRN members receive a 20 % discount.

Please contact Nicole Hecht (nh(at)biorn.org) for the Discount Code and more Information.

New Publication from Sciomics GmbH: Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in NF2-Related Human Schwannoma Cells

Nagel, A.; Hass, E.W.; Hayes, H.; Huelbes, L.; Oliveira, S.; Hardin, H.M.; Marasigan, M.; Nisenbaum, E.; Misztal, C.; Telischi, F.F.; et al. Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in NF2-Related Human Schwannoma Cells. Int. J. Mol. Sci. 2026, 27, 2636. https://doi.org/10.3390/ijms27062636 https://www.mdpi.com/1422-0067/27/6/2636 Simple Summary This study focuses on the action of fimepinostat, a dual histone deacetylase (HDAC)/phosphosphoinositide-3 kinase […]

Fraunhofer IPA wins the “euRobotics Technology Transfer Award” together with Trumpf and Lorch

Technology transfer that works: At the “European Robotics Forum” (ERF) in late March, the trio of applicants won the prestigious award. The award recognizes research that has found its way into industrial applications. The application focused on a “no-code” solution that allows companies to deploy cobots without specialized knowledge or significant welding effort, even for […]

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Paris and Tarrytown, NY, April 13, 2026. The European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in children aged two to 11 years with inadequate response to histamine-1 […]

CDMO Live Europe 2026

Our latest News

New Publication from Sciomics GmbH: Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in NF2-Related Human Schwannoma Cells

Fraunhofer IPA wins the “euRobotics Technology Transfer Award” together with Trumpf and Lorch

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!